Inhibikase Therapeutics, Inc. (IKT) Net margin 2020–2023
Inhibikase Therapeutics, Inc. (IKT) net profit margin by fiscal year — reported net income divided by reported revenue.
-7304.7%FY2023 · since FY2020: -407.7% → -7304.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -7304.7% | +7321.1 pp |
| FY2022 | -14625.9% | -14149.0 pp |
| FY2021 | -476.9% | -69.1 pp |
| FY2020 | -407.7% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice